Hemophilia Treatment Company Catalyst Biosciences’ Antibody Update May Catalyze Shares

/, Health Care Equipment & Services, Healthcare, Insights, Insights-Home, Pharmaceutical & Biotechnology/Hemophilia Treatment Company Catalyst Biosciences’ Antibody Update May Catalyze Shares

Hemophilia Treatment Company Catalyst Biosciences’ Antibody Update May Catalyze Shares

Catalyst Biosciences, Inc. (NASDAQ:CBIO) , a company that is developing improved treatments for hemophilia, expects to update investors on December 18, 2018 regarding its review of the neutralizing antibodies (nAB) observed in Cohort 6 of a phase I/II study earlier this year.

The update by Catalyst should shed more light on the disappointment of the phase I/II results announced six months ago. Catalyst shares declined approximately 60% after the study results were announced.

Catalyst shares traded as high as $37 per share in February before declining to a 52-week low of $8.90 per share in November 2018. The company’s shares rose 6% on December 3 after it released positive data for a different hemophilia drug, activated marzeptacog alfa (MarzAA), on December 1.

Hemophilia Treatment

Hemophilia patients lack the ability to produce blood-clotting factors, principally Factor VIII in Hemophilia A or Factor IX (FIX) in Hemophilia B. Catalyst’s phase I/II study evaluated its FIX variant dalcinonacog alfa (DalcA) in severe Hemophilia B patients.

In two patients in Cohort 6, nABs were observed after administration, indicating the patients’ were reacting to the infusion of DalcA, treating it as a foreign invader even though DalcA is designed to mimic FIX.

Catalyst has since discovered the two patients with the nAB reactions were cousins. The company conducted a comprehensive review of the two Cohort 6 patients since the study results were announced on June 18, 2018.

The update by Catalyst on December 18 may inform the market if the reactions by the two patients were an anomaly. Catalyst could have identified a biomarker in the two patients which would trigger the production of nABs. If so, development of DalcA could proceed with the confidence the drug would work in patients not displaying that biomarker.

In the first five cohorts of the Catalyst phase I/II study, no nABs were observed in any patients, including two different patients in Cohort 6 who had also participated in Cohort 5. At the time of the trial, Catalyst noted patients in Cohort 6 were able to maintain Factor IX levels of more than 30% which is at the upper end of mild hemophilia and higher than currently approved extended half-life (EHL) intravenous Factor IXs.

FVIII deficiency (Hemophilia A) accounts for 80% of such cases and affects 1:5m000 male births, while FIX deficiency, or hemophilia B (HB), affects 1:30,000 male births worldwide.


About the Author:

Before starting SanaCurrents, William (Bill) Langbein spent more than 20 years as a life science business journalist, with stops at California Medicine, In Vivo and Reuters Health. During that time, he wrote on genomic discoveries, the transition of the pharmaceutical companies to rely more on biologics, and the dawn of precision medicine, through which most drug developers came to recognize a one-drug-for-all approach would no longer work. One constant truth he learned is smaller companies deliver the most innovation and highest value to patients and investors. Yet because of the inherent volatility of biopharma and medical devices, small companies typically fly under the radar of investors. The emergence of precision medicine, however, reduces the volatility of small cap companies and increases the potential for strong returns. SanaCurrents was founded to identify the undervalued therapies that would benefit patients and investors the most.

Leave A Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.